Please use this identifier to cite or link to this item:
|Title:||Characterization of cell-free circulating DNA in plasma in patients with prostate cancer|
|Authors:||Delgado, Pamela Oliveira|
Alves, Beatriz Costa A.
Gehrke, Flavia de Sousa
Kuniyoshi, Renata Kelly
Wroclavski, Marcelo Langer
Del Giglio, Auro
Affonso Fonseca, Fernando Luiz [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Cell-free circulating DNA
|Citation:||Tumor Biology. Dordrecht: Springer, v. 34, n. 2, p. 983-986, 2013.|
|Abstract:||Cell-free circulating DNA in plasma and serum may serve as a biomarker for malignant tumor detection and follow up in patients with a variety of solid tumors including prostate cancer. in healthy patients, DNA is normally released from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catastrophe. Cell-free circulating DNA levels were measured by a quantitative real-time PCR method with a set of primers targeted to amplify the consensus ALU apoptotic versus necrotic origin. Prostate cancer patients before and 3 months after diagnosis showed cell-free circulating DNA released at apoptotic and non-apoptotic cell death. Interestingly, all patients after 6 months demonstrated DNA released at non-apoptotic cell. the principal source of cell-free circulating DNA is of apoptotic and non-apoptotic cell death. However, during treatment, this feature could change. Therefore, the study of cell-free circulating DNA would be important to follow the evolution of the disease during the treatment.|
|Appears in Collections:||Em verificação - Geral|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.